Co-Target(s) Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T53904 | Target Info | |||
Target Name | HIF-prolyl hydroxylase 1 (HPH-1) | ||||
Synonyms |
Prolyl hydroxylase domain-containing protein 1; PHD1; Hypoxia-inducible factor prolyl hydroxylase 1; HPH-3; HIF-PH1; HIF-PH; Estrogen-induced tag6; Estrogen-induced tag 6; Egl nine homolog 2; EIT6; EIT-6
Click to Show/Hide
|
||||
Target Type | Successful Target | ||||
Gene Name | EGLN2 | ||||
Biochemical Class | Paired donor oxygen oxidoreductase | ||||
UniProt ID |
Co-Targets of This Target | Top | |||||
---|---|---|---|---|---|---|
Co-Target Name | HIF-prolyl hydroxylase 2 (HPH-2) | Patented-recorded Target | ||||
UniProt ID | EGLN1_HUMAN | |||||
Gene Name | EGLN1 | |||||
Synonyms |
SM-20; Prolyl hydroxylase domain-containing protein 2; PHD2; Hypoxia-inducible factor prolyl hydroxylase 2; HPH-2; HIF-PH2; Egl nine homolog 1; C1orf12
Click to Show/Hide
|
|||||
Representative Drug(s) | FG-4592 | Drug Info | IC50 = 27 nM | Click to Show More | [1] | |
2 | BAY-85-3934 | Drug Info | IC50 = 280 nM | [2] | ||
Co-Target Name | Egl nine homolog 3 (EGLN3) | Co-Target | ||||
UniProt ID | EGLN3_HUMAN | |||||
Gene Name | EGLN3 | |||||
Synonyms |
Prolyl hydroxylase EGLN3; Prolyl hydroxylase domain-containing protein 3; PHD3; HPH-1; Hypoxia-inducible factor prolyl hydroxylase 3; HIF-PH3; HIF-prolyl hydroxylase 3; HPH-3
Click to Show/Hide
|
|||||
Representative Drug(s) | BAY-85-3934 | Drug Info | IC50 = 450 nM | [2] | ||
Co-Target Name | Prolyl 3-hydroxylase OGFOD1 (OGFOD1) | Co-Target | ||||
UniProt ID | OGFD1_HUMAN | |||||
Gene Name | OGFOD1 | |||||
Synonyms |
uS12 prolyl 3-hydroxylase; 2-oxoglutarate and iron-dependent oxygenase domain-containing protein 1; Termination and polyadenylation 1 homolog
Click to Show/Hide
|
|||||
Representative Drug(s) | FG-4592 | Drug Info | IC50 < 1000 nM | [1] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Inhibition of a viral prolyl hydroxylase. Bioorg Med Chem. 2019 Jun 15;27(12):2405-2412. | ||||
REF 2 | Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. Medchemcomm. 2016;7:1271-84. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.